ライフサイエンスコーパス: P for trend

1 nd 1.51 (95% CI, 1.17, 1.95), respectively ( P for trend 0.0015).

2 ed by 0.07 every 2 years (95% CI, 0.04-0.10; p for trend 0.002).

3 R, 1.45; 95% confidence interval, 1.03-2.04; P for trend 0.02).

4 west quartile, RRadj 0.49, 95% CI 0.23-1.05, P for trend 0.024).

5 isit rate remained stable from 1994 to 2009 (p for trend 0.42).

6 0.86 (95% confidence interval: 0.79 to 0.93; p for trend = 0.0002) and 0.80 (95% confidence interval:

7 diseases was negatively associated with NHL (P for trend = 0.0003).

8 er associations found for larger carcinomas (P for trend = 0.0005).

9 nts (P for trend = 0.006), and ever-smokers (P for trend = 0.0005).

10 5) kg/m(2) lower BMI and 7% (95% CI 2%, 12%; P for trend = 0.001) lower risk of overweight or obesity

11 t 30 days (P for trend = 0.008) and 90 days (P for trend = 0.001) was higher across the restrictive s

12 /- 15 ng/ml; >=1.2 g/kg/d, 919 +/- 23 ng/ml; P for trend = 0.001), as were sRAGE concentrations (<0.8

13 97) showed a decreased risk of hypertension (P for trend = 0.001).

14 ts (P for trend = 0.002), and CVD mortality (P for trend = 0.001).

15 cantly associated with thinner average RNFL (P for trend = 0.001).

16 rth increased with the duration of exposure (P for trend = 0.0014).

17 ease mortality (HR, 0.70 [CI, 0.55 to 0.90]; P for trend = 0.002) and a positive association with ova

18 The length of hospital stay (P for trend = 0.002) was longer, and all-cause mortality

19 mortality (P for trend <0.001), CVD events (P for trend = 0.002), and CVD mortality (P for trend = 0

20 = 1.67, 95% confidence interval: 1.08, 2.58; P for trend = 0.002), with stronger associations found f

21 trend = 0.02) and 0.72 (95% CI: 0.57, 0.92; P for trend = 0.002).

22 1 (95% confidence interval (CI): 0.55, 0.92; P for trend = 0.003) and 0.75 (95% CI: 0.59, 0.96; P for

23 elevated risk of rosacea among past smokers (P for trend = 0.003) and with a decreased risk of rosace

24 the E-DII among Southern province residents (P for trend = 0.003), Melanesian women (P for trend = 0.

25 .15 (95% CI: 1.06, 1.24) for poultry intake (P for trend = 0.004), and 1.07 (95% CI: 0.99, 1.16) for

26 s the respective baseline SBP strata listed (p for trend = 0.004).

27 e: for liver, HR = 0.62, 95% CI: 0.42, 0.91; P for trend = 0.004; and for lung, HR = 0.80, 95% CI: 0.

28 26) in those aged 70-89 years at enrollment (P for trend = 0.005).

29 en (P for trend = 0.02), obese participants (P for trend = 0.006), and ever-smokers (P for trend = 0.

30 remained associated with Alzheimer disease (p for trend = 0.007) and all dementia (p for trend = 0.0

31 . unexposed, HR = 4.73, 95% CI: 1.42, 15.76; P for trend = 0.007) was also associated with AN exposur

32 longer, and all-cause mortality at 30 days (P for trend = 0.008) and 90 days (P for trend = 0.001) w

33 < 0.001; women: HR, 0.93 [CI, 0.87 to 0.98]; P for trend = 0.009).

34 . quartile 1, OR = 0.49, 95% CI: 0.31, 0.78; P for trend = 0.01) were inversely associated with ovari

35 = 1.49, 95% confidence interval: 1.04, 2.14; P for trend = 0.01).

36 1-year mortality in a dose-dependent manner (p for trend = 0.01).

37 ncer mortality (HR, 1.31 [CI, 1.07 to 1.61]; P for trend = 0.015).

38 evation, they were 0.77 (95% CI: 0.60, 0.99; P for trend = 0.02) and 0.72 (95% CI: 0.57, 0.92; P for

39 agged 10-year HR = 2.96, 95% CI: 1.38, 6.34; P for trend = 0.02) and pneumonitis (for >3.12 ppm-year

40 = 1.11, 95% confidence interval: 1.01, 1.23; P for trend = 0.02) and several subclasses were positive

41 nts (P for trend = 0.003), Melanesian women (P for trend = 0.02), obese participants (P for trend = 0

42 = 0.83, 95% confidence interval: 0.68, 1.01; P for trend = 0.02), whereas high-fat dairy-food intake

43 ted hazard ratio = 1.13, 95% CI: 1.01, 1.25; P for trend = 0.02).

44 ve serology for hepatitis B surface antigen (P for trend = 0.02).

45 tertiles of arsenic exposure, respectively (P for trend = 0.02).

46 trend = 0.003) and 0.75 (95% CI: 0.59, 0.96; P for trend = 0.02); for AMED and AHEI scores, for mid-f

47 th those with a high school diploma or less (P for trend = 0.02); women with family annual incomes of

48 Mortality rates declined over this period (p for trend = 0.027) from 41.1% in 2004 to 2007 to 33.4%

49 . quartile 1, OR = 0.57, 95% CI: 0.36, 0.92; P for trend = 0.03) and AHEI-2010 (quartile 4 vs. quarti

50 ) for IGFBP-3, and 0.77 (95% CI: 0.57, 1.03; P for trend = 0.03) for IGF-1:IGFBP-3 ratio.

51 ounders, including calcium and fiber intake (P for trend = 0.03), and were restricted to proximal col

52 ted hazard ratio = 1.14, 95% CI: 1.02, 1.28; P for trend = 0.03).

53 f 1.21 (95% confidence interval: 1.02, 1.44; P for trend = 0.03).

54 = 1.35, 95% confidence interval: 0.94, 1.93; P for trend = 0.03).

55 = 0.31) for IGF-1, 1.33 (95% CI: 1.00, 1.76; P for trend = 0.04) for IGFBP-3, and 0.77 (95% CI: 0.57,

56 hood exposure to microbes during early life (P for trend = 0.04).

57 ease (p for trend = 0.007) and all dementia (p for trend = 0.04).

58 ; HR = 1.27) to the distal colon (HR = 1.04; P for trend = 0.040).

59 e number of smokers in the house as a child (P for trend = 0.05) and exposure to 6 or more hours per

60 althy lifestyle had 0.17 (95% CI 0.01, 0.33; P for trend = 0.05) kg/m(2) lower BMI and 7% (95% CI 2%,

61 azard ratio (HR) = 1.43, 95% CI: 1.13, 1.81; P for trend = 0.05), lagged 10 years, that was robust in

62 6, 95% confidence interval (CI): 0.45, 0.98; P for trend = 0.05).

63 ncrease risk of premenopausal breast cancer (p for trend = 0.05).

64 d with those with incomes less than $10,000 (P for trend = 0.055).

65 d with increasing duration of breastfeeding (P for trend = 0.08).

66 = 0.77, 95% confidence interval: 0.64, 0.93; P for trend = 0.08).

67 = 0.64, 95% confidence interval: 0.35, 1.17; P for trend = 0.09), especially for adenocarcinomas, but

68 % CI: 0.99, 1.16) for fish/shellfish intake (P for trend = 0.12).

69 etween alteplase dose and the extent of MVO (p for trend = 0.128).

70 = 1.36, 95% confidence interval: 0.84, 2.21; P for trend = 0.17).

71 = 0.80, 95% confidence interval: 0.56, 1.14; P for trend = 0.20) or as a log-transformed continuous v

72 = 1.54, 95% confidence interval: 0.75, 3.16; P for trend = 0.21).

73 ult exposure (HR = 2.15, 95% CI: 1.23, 3.73; P for trend = 0.23), and was marginally significantly hi

74 1 (95% confidence interval (CI): 0.68, 1.23; P for trend = 0.31) for IGF-1, 1.33 (95% CI: 1.00, 1.76;

75 = 1.01, 95% confidence interval: 0.97, 1.05; P for trend = 0.35).

76 7, 95% confidence interval (CI): 0.91, 1.03; P for trend = 0.43).

77 = 0.62, 95% confidence interval: 0.29, 1.30; P for trend = 0.56).

78 5% confidence interval (95% CI): 0.77, 1.17; P for trend = 0.63) compared with those who never did sh

79 = 0.95, 95% confidence interval: 0.64, 1.43; P for trend = 0.64).

80 , -4.3, -4.7, and -10.6 mm Hg, respectively (p for trend = 0.66).

81 = 1.15, 95% confidence interval: 0.82, 1.60; P for trend = 0.67).

82 information (HR = 1.40, 95% CI: 1.00, 1.97; P for trend = 0.74).

83 or fatal CHD were maintained but attenuated (P for trend =0.02), whereas the significant associations

84 ), and women (9.5% in 2015 to 10.6% in 2017, P(for trend)=0.2).

85 nged for men (10.4% in 2015 to 9.9% in 2017, P(for trend)=0.3), and women (9.5% in 2015 to 10.6% in 2

86 ion in DNT was particularly marked in China (P for trend, 0.001), but was not significant across the

87 associated with incident HF hospitalization (P for trend, 0.001).

88 th diabetes mellitus increased (36.0%-55.3%; P for trend, 0.005).

89 nt across the other participating countries (P for trend, 0.065).

90 dian, 70 years [interquartile range, 62-77]; P for trend, 0.14), but the proportion with diabetes mel

91 atio, 1.99; 95% CI, 1.52-2.60, respectively; P for trend, 0.34).

92 D recipients-25.8% in 2004 to 21.9% in 2016 (P for trend, 0.91).

93 lowest quartile with a difference of 1.69% (p for trend: 0.01).

94 2; 95% confidence interval [CI]: 1.49-10.27; P for trend: 0.011) and multivariate-adjusted analyses (

95 er 1-SD increment: 0.91; 95% CI: 0.82, 0.98; P for trend: 0.021).

96 er 1-SD increment: 0.95; 95% CI: 0.91, 0.99; P for trend: 0.023).

97 showed 28% reduced risk (95% CI: 0.54, 0.93; P for trend: 0.031) of BC compared with the lowest intak

98 he lowest quartile with difference of 4.00% (p for trend: 0.04) and 3.90% (p for trend: 0.05), respec

99 ence of 4.00% (p for trend: 0.04) and 3.90% (p for trend: 0.05), respectively.

100 usted analyses (HR, 2.68; 95% CI: 1.02-7.03; P for trend: 0.072).

101 7 to -71]) versus normal glucose metabolism (P for trend=0.001).

102 to -0.25]) versus normal glucose metabolism (P for trend=0.001).

103 ratio of 0.94, P=0.808, with SBP>136 mm Hg (P for trend=0.001).

104 27% in 1995 to 1999 to 32% in 2010 to 2014 ( P for trend=0.002), with the largest increase observed i

105 est quartile was 0.53 (95% CI 0.33 to 0.84) (P for trend=0.006).

106 >/=once/week, HR=1.17 (95% CI: 1.02, 1.34)] (p for trend=0.01).

107 etter neurological outcomes among survivors (P for trend=0.01).

108 for trend<0.001) and 2-hour glucose levels (P for trend=0.015).

109 g, and 0.76 (95% CI, 0.57-1.01) for 300 mg ( P for trend=0.025).

110 acid was inversely associated with PD risk (P for trend=0.033).

111 er in those at higher baseline risk (1-sided P for trend=0.04), with high-risk (2 points) and very-hi

112 eased with increasing duration of lactation (P for trend=0.04).

113 g, and 0.78 (95% CI, 0.60-1.02) for 300 mg ( P for trend=0.042).

114 pared with shorter durations of clopidogrel (P for trend=0.06).

115 o, 0.68; 95% confidence interval, 0.34-1.37; P for trend=0.13).

116 prescriptions: HR = 2.06, 95% CI, 0.82-5.16; P for trend = .002).

117 (hazard ratio [HR] 0.48; 95% CI, 0.28-0.83; P for trend=.003) and 30% reduced risk of all-cause deat

118 tality risk (HR, 0.69; 95% CI, 0.49 to 0.98; P for trend = .006), independent of prediagnosis activit

119 door smokers, aRR, 1.30 [95% CI, 1.02-1.64]; P for trend = .006; PAF, 7.2% [95% CI, 2.2%-12.0%]), and

120 h asthma or recurrent wheeze by age 3 years (P(for trend) = .008).

121 0.5] days in 2001 vs 7.6 [0.6] days in 2012, P for trend = .009), but in-patient mortality remained u

122 % CI, 1.11-1.73) for 6 years or more of use (P for trend = .009).

123 <25 vs >/=35: HR, 1.33 [95% CI, 0.90-1.97]; P for trend = .01) and African American men, although th

124 ay was 0.82 for all POAG (95% CI, 0.69-0.97; P for trend = .02) and 0.52 for POAG with paracentral VF

125 ovement among black patients on an absolute (P for trend = .02) and relative scale (P for interaction

126 <25 vs >/=35: HR, 0.80 [95% CI, 0.58-1.09]; P for trend = .02) but positively associated with risk w

127 erved over time, favoring time-based events (P for trend = .02).

128 ately 240 mg/d) was 0.79 (95% CI, 0.66-0.93; P for trend = .02).

129 <25 vs >/=35: HR, 1.81 [95% CI, 0.79-4.11]; P for trend = .02).

130 e mortality (HR, 0.80; 95% CI, 0.68 to 0.95; P for trend = .021).

131 g African American men with BMI at least 35 (P for trend = .03).

132 azard ratio [HR], 1.49 [95% CI, 0.95, 2.34]; P for trend = .03).

133 sion to active asthma from age 3 to 6 years (P(for) (trend) = .04).

134 <25 vs >/=35: HR, 2.22 [95% CI, 1.17-4.21]; P for trend = .05).

135 gioid streaks was associated with older age (P for trend = 1.92 x 10(-15)) and a higher prevalence of

136 allelic hazard ratio (HR)=1.81 (1.49-2.19); P for trend=1.90 x 10(-9)).

137 s quintile 1 MVRR = 0.82; 95% CI, 0.67-1.01; P for trend = .11; 486 case patients with IOP <22 mm Hg:

138 s quintile 1 MVRR = 0.71; 95% CI, 0.53-0.96; P for trend = .12).

139 tality risk (HR, 1.25; 95% CI, 0.93 to 1.67; P for trend = .126).

140 porting use of any supplements in 2011-2012 (P for trend = .19).

141 The breast cancer RRs declined with age (P for trend = 2.0 x 10(-3)).

142 reasing or decreasing trend in all patients (P for trend = .22) and in the large femoral access subgr

143 er prevalence of CNV and/or macular atrophy (P for trend = 4.22 x 10(-10) and P for trend = 5.17 x 10

144 ng either definition, over the study period (P for trend = .46).

145 ar atrophy (P for trend = 4.22 x 10(-10) and P for trend = 5.17 x 10(-6), respectively).

146 s quintile 1 MVRR = 0.85; 95% CI, 0.68-1.06; P for trend = .50).

147 (7.8% [1.1%] in 2001 vs 6.3% [1.7%] in 2012, P for trend = .54).

148 score were decreased and increased (log-rank ps for trend: 6 x 10E-4 and 9 x 10E-45), respectively.

149 5% CI: 1.3 to 2.1) for allele score 7 to 10 (p for trend: 9 x 10(-5)).

150 o, 1.56; 95% confidence interval, 1.17-2.08; P for trend across quartiles=0.003).

151 for trend <0.001, P for nonlinearity <0.001; P for trend differences >0.05) risks.

152 herapy (MHT; HR, 1.16; 95% CI, 1.03 to 1.30; P for trend for duration = .001).

153 11.2% in men and from 5.7% to 8.7% in women (P for trends for both groups < 0.001).

154 cal stages of diagnosis or tumor grades (all P for trend > 0.1).

155 ISU]; P for trend < .001 [for percentages], P for trend < .001 [for levels]).

156 s (24% +/- 20%; 3 ISU [95% CI, 2.4-3.4 ISU]; P for trend < .001 [for percentages], P for trend < .001

157 s with higher annual and cumulative volumes (P for trend < .001 for all).

158 % vs 16.7% and 52.9% vs 14.2%, respectively; P for trend < .001 for both scores).

159 decreasing trend with higher annual volumes (P for trend < .001 for both) to a sensitivity of 81% and

160 prescriptions: HR = 3.65, 95% CI, 2.64-5.05; P for trend < .001) and possible CKD (0 prescriptions: H

161 o 19% (difference, 14% [95% CI, 12% to 17%], P for trend < .001) and use of fish oil supplements incr

162 of patients with VT/VF OHCA (46.9% to 60.1%, P for trend < .001) in those with STE (59.2% to 74.3%, P

163 prescriptions: HR = 2.54, 95% CI, 1.81-3.57; P for trend < .001) or possible CKD (1-2 prescriptions:

164 d < .001) in those with STE (59.2% to 74.3%, P for trend < .001) or without STE (43.3% to 56.8%, P fo

165 12% (difference, 11% [95% CI, 9.1% to 12%], P for trend < .001) over the study period, whereas use o

166 s quintile 1 MVRR = 0.56; 95% CI, 0.40-0.79; P for trend < .001) than for POAG with peripheral VF los

167 sk of death increased with increasing stage (P for trend < .001), and patients with stage III disease

168 n 2012 (odds ratio, 2.47; 95% CI, 2.25-2.71; P for trend < .001), and PCI increased from 9.5% in 2000

169 prescriptions, HR = 2.48, 95% CI, 1.80-3.42; P for trend < .001), as was use of anticonvulsants (defi

170 prescriptions: HR = 2.88, 95% CI, 2.17-3.81; P for trend < .001), whereas use of anticonvulsants, ant

171 o <5; 1.47; 95% CI, 1.16-1.85 for NLR >/= 5; P for trend < .001).

172 (difference, -5.7% [95% CI, -8.6% to -2.7%], P for trend < .001).

173 n 2012 (odds ratio, 4.80; 95% CI, 4.21-5.66; P for trend < .001).

174 rend < .001) or without STE (43.3% to 56.8%, P for trend < .001).

175 with paracentral VF loss (95% CI, 0.29-0.96; P for trend < .001).

176 arotenoid index was 0.65 (95% CI, 0.53-0.80; P for trend < .001).

177 extreme quintiles = 0.59; 95% CI, 0.48-0.73; P for trend < .001).

178 Is improved from 11% in 2003 to 93% in 2013 (P for trend < .001).

179 prescriptions: HR = 1.97, 95% CI, 1.34-2.90; P for trend < .001).

180 reased in patients with STE (53.7% to 87.2%, P for trend < .001, and 29.7% to 77.3%, P for trend < .0

181 vely) and those without STE (19.3% to 33.9%, P for trend < .001, and 3.5% to 11.8%, P for trend < .00

182 29.5% in adults without a history of cancer (P for trend < .001, both groups).

183 .2%, P for trend < .001, and 29.7% to 77.3%, P for trend < .001, respectively) and those without STE

184 3.9%, P for trend < .001, and 3.5% to 11.8%, P for trend < .001, respectively).

185 prescriptions, HR = 2.30, 95% CI, 1.53-3.44; P for trend < .001; possible CKD, 1-2 prescriptions: HR

186 .0%, the opposite relationship was observed (p for trend < 0.0001 and 0.0027, respectively).

187 e were 2.2, 3.3, 4.0, and 9.9, respectively (P for trend < 0.0001) after adjustment for other risk fa

188 est quintile: HR = 1.28, 95% CI: 1.13, 1.45; P for trend < 0.0001) and lower risk of both liver and l

189 A was positively associated with ALT levels (p for trend < 0.0001), indicating possible liver toxicit

190 eased risk of rosacea among current smokers (P for trend < 0.0001).

191 and for lung, HR = 0.80, 95% CI: 0.72, 0.88; P for trend < 0.0001).

192 - 31 pg/ml; >=1.2 g/kg/d, 1574 +/- 47 pg/ml; P for trend < 0.0001).

193 but with cancer mortality only among whites (P for trend < 0.0001).

194 coefficient of variation, and hypoglycemia (p for trend < 0.0001, < 0.0001, and 0.0010, respectively

195 = 1.10, 95% confidence interval: 1.06, 1.15; P for trend < 0.001) and acetaminophen use (for >6 years

196 days) to 12.7 days (CI, 11.2 to 14.3 days) (P for trend < 0.001) and across levels of long-form s

197 ease mortality (HR, 0.78 [CI, 0.68 to 0.90]; P for trend < 0.001) and cerebrovascular disease mortali

198 9 to 2.63]; and HR, 2.63 [CI, 1.60 to 4.30]; P for trend < 0.001) and longer sedentary bout duration

199 tality for men (HR, 0.41 [CI, 0.32 to 0.54]; P for trend < 0.001) and women (HR, 0.60 [CI, 0.46 to 0.

200 = 1.09, 95% confidence interval: 1.04, 1.14; P for trend < 0.001) were associated with higher risks o

201 0 to 1.85]; and HR, 1.96 [CI, 1.31 to 2.93]; P for trend < 0.001) were both associated with a higher

202 erval (CI): 1.14, 1.33) for red meat intake (P for trend < 0.001), 1.15 (95% CI: 1.06, 1.24) for poul

203 with an increase in the blood pressure (BP) (P for trend < 0.001), and were increased in the hyperten

204 independently associated with BMI in women (P for trend < 0.001), but not in men.

205 sk of colon cancer in age-adjusted analyses (P for trend < 0.001).

206 4 cups per day: HR, 0.82 [CI, 0.78 to 0.87]; P for trend < 0.001).

207 001) and women (HR, 0.60 [CI, 0.46 to 0.78]; P for trend < 0.001).

208 which was associated with increased BMI (all p for trend < 0.001).

209 association between sitting time and NAFLD (P for trend < 0.001).

210 .7 mug/m3) quartiles of PM2.5, respectively (p for trend < 0.001).

211 days) to 11.9 days (CI, 10.8 to 12.9 days) (P for trend < 0.001).

212 ality (men: HR, 0.88 [95% CI, 0.82 to 0.95]; P for trend < 0.001; women: HR, 0.93 [CI, 0.87 to 0.98];

213 = 0.60, 95% confidence interval: 0.41, 0.89; P for trend < 0.01) and to horse farming (>/=20 years: h

214 .27 kg/year less weight (95% CI: 0.12, 0.41; P for trend < 0.01) during the 10-year follow-up.

215 nificantly increased odds ratios of obesity (P for trend < 0.01) in women.

216 , grains, egg) and most other allergy diets (P for trend < 0.01).

217 intile) = 2.75; 95% CI, 1.47-5.15; p < 0.01; p for trend < 0.01).

218 st quartile (mean, 27.7, 95% CI: 27.0, 28.4; P for trend < 0.01).

219 octane sulfonate and perfluorooctanoic acid (P for trend < 0.01).

220 vascular disease mortality in each subgroup (P for trend < 0.03) but with cancer mortality only among

221 ncluded adjustment for IGF-1 concentrations (P for trend < 0.05).

222 with evidence of dose-response relationship (P for trend < 0.05).

223 e patients (15.8% in 2000 and 23.2% in 2014; P for trend <.001 for both), with greater survival impro

224 OR, 0.38 [95% CI, 0.29-0.49]), respectively (P for trend <.001 in both comparisons).

225 (1.36-3.51) for Q1 (P = .001) (worst scores; P for trend <.001) after adjustment for sex and educatio

226 ll-cause death (HR, 0.70; 95% CI, 0.54-0.91; P for trend <.001).

227 cantly from 2001 through 2012 (3177 vs 1345, P for trend <.001).

228 nts, OR, 2.13 [95% CI, 1.66-2.75], P < .001; P for trend <.001).

229 from 2001 through 2012 ($29 507 vs $79 607, P for trend <.001).

230 011-2012 (difference, 8% [95% CI, 3.8%-12%]; P for trend <.001).

231 -2012 (difference, 6.6% [95% CI, 4.4%-8.2%]; P for trend <.001).

232 76-.83) for counties with >/=31% vaccinated (P for trend <.001).

233 th an increased risk of cataract extraction (P for trend <.001).

234 equency of MACCE declined from 3.1% to 2.6% (P for trend <.001; adjusted odds ratio [aOR], 0.95; 95%

235 stroke from 0.52% in 2004 to 0.77% in 2013 (P for trend <.001; aOR 1.79; CI 1.73-1.86).

236 quartile versus the lowest quartile of fT4; P for trend </=0.001 across quartiles).

237 mpared with those least socially integrated (P for trend <0.0001).

238 eneous GGNs 36.4%; part-solid nodules 85.5%, P for trend <0.0001).

239 mg, prasugrel, and ticagrelor, respectively; P for trend <0.0001).

240 n 20 years and gradually increased with age (p for trend <0.0001).

241 nd 2.10 (95% CI, 1.58, 2.80), respectively ( P for trend <0.0001).

242 rtality, and HCC in a dose-dependent manner (P for trend <0.0001, <0.0001, and 0.009, respectively).

243 chemic stroke and the individual components (P for trend <0.001 for all).

244 R, 2.61; 95% confidence interval, 1.81-3.78; P for trend <0.001) and BNP (aHR, 1.45; 95% confidence i

245 terol of up to 0.61 mmol/l (24 mg/dl; 18.2%; p for trend <0.001) and with lower cardiovascular mortal

246 identified a >20-fold gradient of HHF risk (P for trend <0.001) in both the derivation and validatio

247 0.001), CHD (HR: 1.46; 95% CI: 1.36 to 1.56; p for trend <0.001), and stroke (HR: 1.28; 95% CI: 1.17-

248 95% confidence interval [CI]: 1.31 to 1.46; p for trend <0.001), CHD (HR: 1.46; 95% CI: 1.36 to 1.56

249 as associated with higher risk of mortality (P for trend <0.001), CVD events (P for trend = 0.002), a

250 0.80 (95% confidence interval: 0.72 to 0.89; p for trend <0.001), respectively.

251 led during the study period (21.4% to 59.3%; P for trend <0.001), thereby decreasing time from emerge

252 eclined from 61.0% in 2002 to 49.0% in 2014 (P for trend <0.001), while mortality for males declined

253 risk of CKD and PAD with higher LDL-C (both p for trend <0.001), with hazard ratios of 1.05 (95% con

254 eclined from 48.6% in 2002 to 32.2% in 2014 (P for trend <0.001).

255 ars of age (aRR: 1.27; 95% CI: 1.19 to 1.36; p for trend <0.001).

256 coronary heart disease and stroke combined (p for trend <0.001).

257 , -7.5, -9.7, and -20.8 mm Hg, respectively (p for trend <0.001).

258 95% confidence interval [CI]: 1.85 to 2.33; p for trend <0.001).

259 ncreasing body surface area affected by PsO (P for trend <0.001).

260 red with 1.6% in patients with a score </=9 (P for trend <0.001).

261 interval, 1.07-1.61) for hs-cTnT >/=14 ng/L (P for trend <0.001).

262 R, 1.94; 95% confidence interval, 1.41-2.68; P for trend <0.001).

263 ], 2.19; 95% confidence interval, 1.56-3.06; P for trend <0.001).

264 o 4 versus no age-related signs at baseline (P for trend <0.001).

265 and stroke (HR: 1.28; 95% CI: 1.17- to 1.39; p for trend <0.001).

266 of child asthma across the maternal groups (P for trend <0.001).

267 , 4.73; 95% confidence interval, 2.20-10.07; P for trend <0.001).

268 and the presence of moderate to severe WMH (p for trend <0.001).

269 significant in 90-day conditional survivors (P for trend <0.001).

270 lower) 90-day SMR had longer graft survival (P for trend <0.001).

271 gnificantly differed between neighborhoods ( P for trend <0.001).

272 ars of age (aRR: 2.67; 95% CI: 2.37 to 3.01; p for trend <0.001); SNF admission risk was highest in t

273 macrosomia, SGA, and perinatal infant death (P for trend <0.001, <0.001, <0.001, 0.001, <0.001).

274 ry heart disease (P for heterogeneity=0.001, P for trend <0.001, P for nonlinearity <0.001) and strok

275 0.001) and stroke (P for heterogeneity=0.07, P for trend <0.001, P for nonlinearity <0.001; P for tre

276 Warfarin use decreased from 52.4% to 34.8% (p for trend <0.01), and DOAC use increased from 0% to 25

277 1), and DOAC use increased from 0% to 25.8% (p for trend <0.01).

278 m 52.4% to 60.7% among eligible AF patients (p for trend <0.01).

279 d with all-cause mortality in all subgroups (P for trend <= 0.005); for the most isolated versus the

280 from the highest to the lowest apoE tertile (p for trends < 1 x 10(-6) ).

281 9), 0.80 (0.74, 0.86) and 0.80 (0.74, 0.87) (p for trend = <0.001) for 0, 1-60, 61-150, 151-300, and

282 ), 0.83 (0.69, 1.00), and 0.70 (0.57, 0.85) (p for trend = <0.001) for cycling 0, 1-60, 61-150, and >

283 d<0.0001) and diabetes mellitus (25% to 35%, P for trend<0.0001) also increased among young AMI patie

284 History of hypertension (59% to 73%, P for trend<0.0001) and diabetes mellitus (25% to 35%, P

285 atic model assessment of insulin resistance (P for trend<0.001) and 2-hour glucose levels (P for tren

286 creasing usage over the time period studied (P for trend<0.001).

287 creased with increasing months of lactation (P for trend<0.01), whereas among obese women (BMI>/=30),

288 Bleeding increased across risk groups (P for trend<0.01); however, net clinical outcome was inc

289 1.8%; and for scores of 13-15, it was 72.1% (P for trend, <.0001).

290 62 (95% CI, 2.17-3.08), an increase of 205% (P for trend, <.001).

291 05 (95% CI, 0.87-1.23), an increase of 950% (P for trend, <.001).

292 7 (95% CI, 9.48-10.85), an increase of 176% (P for trend, <.001).

293 71 (95% CI, 3.44-3.98), an increase of 165% (P for trend, <.001).

294 51 (95% CI, 2.21-2.80), an increase of 161% (P for trend, <.001); poisonings involving methadone incr

295 od 1997 to 2006 compared with 2007 to 2017 ( P for trend, <0.001), which was partially offset by an i

296 2017 (2.5% [1997-2006] to 4.6% [2007-2017]; P for trend, <0.001).

297 ed from 8.7% to 7.3% between 1997 and 2017 ( P for trend, <0.001; 1997-2006 versus 2007-2017).

298 ed with the severity of cytological results (P for trend, <0.05).

299 to unnatural cause were analyzed separately (P for trend or difference < 0.0001), and for women with

300 e spirometric pattern [FVC < 60% predicted], P for trend test < 0.001).